Recombinant Technologies Is Raising Capital To Roll Out A Game Changing Alzheimer'S Treatment

Sep 27, 2021•almost 4 years ago

Cheshire

Description

Ask anyone who spent time with a close friend or family member with Alzheimer's Disease and they'll tell you they wouldn't wish it on their worst enemy. Alzheimer's hits everybody hard; not just the sufferer who struggles with unimaginable frustration trying to remember the simplest of things; everyone around them feels pain and anguish watching someone close to them suffer. Recombinant Technologies has developed a unique treatment to a devastating medical problem to alleviate the anguish and bring relief.

Company Information

Company

Technologies

Location

Cheshire, Connecticut, United States

About

The company has developed an innovative treatment that addresses the cause of the disease rather than the symptoms. The company has developed a patented molecule (AmyTrap) with demonstrated success in animal-model proof of concept studies to remove amyloid-beta, which is the physiological cause behind the plaque buildup in the brain associated with Alzheimer's Disease. Alzheimer's hits everybody hard; not just the sufferer who struggles with unimaginable frustration trying to remember the simplest of things; everyone around them feels pain and anguish watching someone close to them suffer. Recombinant Technologies has developed a unique treatment to a devastating medical problem to alleviate the anguish and bring relief.Continue Reading Recombinant Technologies has received multiple peer-reviewed grants (which in itself is a stamp of approval) from the National Institutes of Health to develop this Amytrapper devices.